Desmoid tumour
The EU has approved 1 indication of 1 drug in desmoid tumour. None of them needs a biomarker result.
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| No biomarker required1 | ||||
Ogsiveo | None | Monotherapy | Any line | Progressing; requiring systemic treatment |
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Nirogacestat (Ogsiveo)
Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.